Presented by: Christoph Schifflers, Martijn Vlaming, Emmanuelle Sidot, Jezabel Lefèvre, Elise Pepermans (ImmunSpec, Niel, Belgium), Ellen Boelen and Sofie Pattyn
Presented at: American Association for Cancer Research (AACR) Annual Meeting, April 25-30, 2025, Chicago, IL
Therapeutic vaccination is a promising strategy for personalized cancer therapy. Using this approach, an adaptive T cell mediated immune response can be mounted against peptides presented by cancer cells, allowing for a systemic cancer cell eradication and immune memory formation.
A key challenge for this approach is the identification of target peptides that are ubiquitously presented by cancer cells and capable of eliciting a long-lasting cytotoxic T cell response. In this context, IQVIA Laboratories In Vitro Immunology developed a pipeline for the Target Peptide Identification and the (functional) Peptide Evaluation (TPIPE) using in vitro generated peptide-specific T cells. This approach can be customized to be applicable to various therapeutic vaccine platforms.
Complete the form below to access this scientific poster.
